ATVB: Benefits of statins for COVID-19-related outcomes

Although statins are widely prescribed as lipid-lowering drugs, the safety of their use in the new coronary pneumonia COVID-19 epidemic is a concern because statins increase the expression of ACE2.
recently, Arteriosclerosis, Thrombosis, andVascular Biology, an authoritative journal in the field of cardiovascular medicine, published a research paper that aims to reveal the relationship between statins and 60-day mortality in patients with COVID-19.
all laboratory-confirmed COVID-19 patients in Korea participated in the study between 19 January and 16 April 2020.
researchers assessed the association between statin use and COVID-19-related mortality through an overall and nested 1:2 tendency score matching study.
, the researchers compared coVID-19 patients in South Korea between January 2019 and June 2019 with the risk of death in patients hospitalized with pneumonia in retrospective cohorts.
age of 10,448 COVID-19 patients was 45.
533 (5.1%) patients took statins.
After adjusting for age, gender, and comedies, Cox's regression showed a significant reduction in the risk ratio associated with statin use (risk ratio of 0.637 (95% CI is 0.425-0.953) ;P=0.0283).
, statins had similar benefits when comparing the risk ratio of patients with COVID-19 and those with pneumonia in retrospective cohorts.
results, statin use was significantly associated with lower mortality rates in COVID-19 patients and was consistent with results in pneumonia patients.